title: [Effect and tolerability of sequential administration of estradiol valerate and medroxyprogesterone acetate on menopausal symptoms, hormonal profile and biochemical markers in climacteric women].
abstract: Hormonal replacement therapy is the gold standard in the treatment and prophylaxis of menopausal symptoms and osteoporosis.
  
  
  OBJECTIVE
  Of the study was to assess changes in climacteric symptoms, hormonal profile and biochemical parameters during sequential hormonal replacement therapy in climacteric women 19 women aged 46-61 years old was included into the study. We evaluated Kuppermann's index, serum concentration of estradiol, FSH, morphology of the blood, lipids and haemostatic parameters.
  
  
  RESULTS
  The menopausal symptoms significantly decreased. Lipids levels, haemostatic parameters and morphological parameters of the blood didn't change.
  
  
  CONCLUSIONS
  The sequential hormonal replacement therapy with estradiol valerate and medroxy-progesterone acetate is efficient and safe.
authors.affiliation: Kliniki Endokrynologii Ginekologicznej AM w Warszawie.
authors.forename: Stanisław
authors.initials: S
authors.lastname: Radowicki
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Skórzewska
authors.forename: Barbara
authors.initials: B
authors.lastname: Borakowska
authors.forename: Waldemar
authors.initials: W
authors.lastname: Wierzba
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Michalewski
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood*; D001779:Blood Coagulation Factors / Q000378:metabolism; D015519:Bone Density; D002979:Climacteric / Q000097:blood / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000494:pharmacology; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D001779:Blood Coagulation Factors; D004966:Estrogens, Conjugated (USP); D008055:Lipids; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D017258:Medroxyprogesterone Acetate